Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously untreated NHL and the efficacy and safety of BsAbs used in combination remain uncertain. We su...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology & oncology 2023-04, Vol.12 (1), p.41-41, Article 41
Main Authors: Lin, Zhijuan, Liu, Long, Li, Zhifeng, Xu, Bing
Format: Article
Language:English
Subjects:
Antibodies
B cells
Bispecific antibodies
Cancer
Chemotherapy
Conferences, meetings and seminars
Correspondence
Cytokines
Diffuse large B-cell lymphoma
Follicular lymphoma
Hematology
Investigations
Lymphoma
Non-Hodgkin's lymphomas
Response rates
Stem cells
Transplants & implants
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously untreated NHL and the efficacy and safety of BsAbs used in combination remain uncertain. We summarized data published at the 64th American Society of Hematology (ASH) Annual Meeting on BsAb monotherapy or combination therapy for first-line or relapsed/refractory B-NHL. BsAb monotherapy in elderly/unfit newly diagnosed (ND) DLBCL patients achieved ORR and CR rates of 56% and 43%, respectively. In addition, BsAbs combined with chemotherapy or other novel agents raised the ORR higher than 50% without increasing the incidence of grade ≥ 3 CRS. We conclude that BsAb monotherapy or combination therapy for first-line or relapsed/refractory B-NHL has high efficacy and satisfactory safety.
ISSN:2162-3619
2162-3619
DOI:10.1186/s40164-023-00404-3